UPDATE: Wedbush Initiates Coverage on Curis on Potential of New Oral Therapies
In a report published Friday, Wedbush analyst Christopher N. Marai initiated coverage on Curis (NASDAQ: CRIS) with an Outperform rating and $6.00 price target.
In the report, Wedbush noted, “Curis is a drug company developing oral therapies for oncology based on knowledge of cell signaling pathways. CRIS is developing CUDC-427, an antagonist of inhibitor of apoptosis proteins, key regulators of cancer cell death that may overcome chemotherapy resistance. It is also developing CUDC-907, a dual HDAC/PI3K inhibitor with differentiated PK/PD properties for DLBCL and MM. CRIS receives royalties from its partner Roche on sales of Erivedge, an approved hedgehog pathway inhibitor for advanced basal cell carcinoma.”
Curis closed on Thursday at $3.38.
Latest Ratings for CRIS
|May 2016||Cowen & Company||Assumes||Outperform|
|Mar 2016||SunTrust Robinson Humphrey||Initiates Coverage on||Buy|
|Aug 2015||FBR Capital||Initiates Coverage on||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.